Core Viewpoint - Shengnuo Biopharmaceutical (688117.SH) announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has received the approval notice for the marketing application of the active pharmaceutical ingredient, Vepagliflozin, from the National Medical Products Administration (NMPA) [1] Group 1 - The approved drug, Vepagliflozin, is a polyethylene glycol (PEG) modified version of Exenatide, which acts as a GLP-1 receptor agonist [1] - Vepagliflozin mimics the physiological effects of natural human GLP-1 by enhancing insulin secretion in a glucose-dependent manner, thereby lowering blood sugar levels [1] - The drug is intended for the treatment of type 2 diabetes and obesity [1]

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has received approval from the National Medical Products Administration for the marketing application of its active pharmaceutical ingredient, Vepagliflozin [1] Group 1: Company Developments - Shengnuo Biopharmaceutical's wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has recently obtained the approval notice for Vepagliflozin from the National Medical Products Administration [1] - Vepagliflozin is a polyethylene glycol (PEG) modified version of Exenatide, which acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural human GLP-1 [1] Group 2: Product Information - The drug enhances insulin secretion in a glucose-dependent manner, thereby lowering blood sugar levels, and is intended for the treatment of type 2 diabetes and obesity [1]

Core Viewpoint - The approval of the raw material drug Weipinatin by the National Medical Products Administration represents a significant achievement for the company, showcasing its comprehensive strengths in research, production, and quality management systems [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has received the approval notice for the marketing application of Weipinatin raw material drug [1] - Weipinatin is a polyethylene glycol-conjugated exenatide that acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural human GLP-1 [1] Group 2: Therapeutic Use - The drug is designed to enhance insulin secretion in a glucose-dependent manner, thereby lowering blood sugar levels, which is beneficial for the treatment of type 2 diabetes and obesity [1] Group 3: Strategic Implications - The approval is expected to accumulate valuable experience for the company's future drug research and development, positively impacting its operational growth [1]

Core Insights - The CDMO industry is experiencing a competitive landscape characterized by "head concentration, niche breakthroughs, and increasing differentiation" with leading companies like WuXi AppTec dominating the market share [1] - The growth of the peptide CDMO sector is significantly driven by the expansion of GLP-1 drugs, which has led to substantial revenue increases for several companies [4][14] - The competition is shifting from cost advantages to technological depth, with companies focusing on specialized areas like peptide CDMO to carve out their niches [1][6] Industry Overview - WuXi AppTec services 8 out of 40 small molecule drugs approved by the FDA from 2024 to the first half of 2025, indicating its irreplaceable value in the global market [1] - Other CDMO companies, such as Kelaiying and Saintno Bio, are focusing on peptide CDMO and achieving above-average growth rates, forming a "high-growth camp" within the industry [1][4] - The CXO sector saw a 12% revenue growth year-on-year in Q1 to Q3 of 2025, with net profit increasing by 58%, highlighting a positive growth trend across the industry [2] Company Performance - Kelaiying reported a total revenue of 4.63 billion yuan in the first three quarters of 2025, with peptide and oligonucleotide segments growing by 72% year-on-year, and peptide revenue increasing by over 150% [4] - Saintno Bio's revenue grew by 54% year-on-year, with net profit increasing by 123%, primarily driven by its peptide business [4] - Notably, the combined sales of GLP-1 drugs from Novo Nordisk and Eli Lilly reached approximately $50.2 billion in the first three quarters of 2025, underscoring the market's potential [4] Technological Advancements - The shift from scale advantages to technological premiums is evident, as companies must innovate to meet the complex demands of new therapies [6] - Kelaiying is leveraging its expertise in small molecule CDMO to expand into peptide and other large molecule areas, enhancing its production capabilities [8] - Companies like Nuotai Bio and Saintno Bio are developing specialized technologies for peptide synthesis, which allows them to maintain competitive advantages in the market [10][11] Market Dynamics - The entry of numerous pharmaceutical companies into the GLP-1 market has rapidly expanded the global peptide market, benefiting the peptide CDMO sector [5] - The competition is expected to evolve as the market transitions from a shortage to an oversupply, necessitating a focus on technological innovation and ecosystem building [16] - Future growth in the peptide sector may be driven by innovations in multi-target peptide drugs and the application of AI in drug design [14][15]

分组1 - Shengnuo Biotech announced a cash dividend of RMB 0.03176 per share, with the record date on November 14, 2025, and the ex-dividend date on November 17, 2025 [1] - Jiangsu Guotai declared a cash dividend of RMB 1.70 per 10 shares (including tax), with the record date on November 17, 2025, and the ex-dividend date on November 18, 2025 [1] - Dabeinong issued a cash dividend of RMB 0.30 per 10 shares (including tax), with the record date on November 17, 2025, and the ex-dividend date on November 18, 2025 [1] 分组2 - Rongmei Co. announced a cash dividend of RMB 1.32 per 10 shares (including tax), with the record date on November 17, 2025, and the ex-dividend date on November 18, 2025 [2] - Kaisheng New Materials declared a cash dividend of RMB 0.50 per 10 shares (including tax), with the record date on November 17, 2025, and the ex-dividend date on November 18, 2025 [2] - Guilin Sanjin issued a cash dividend of RMB 2.00 per 10 shares (including tax), with the record date on November 18, 2025, and the ex-dividend date on November 19, 2025 [2] 分组3 - Longhua New Materials announced a cash dividend of RMB 0.70 per 10 shares (including tax), with the record date on November 18, 2025, and the ex-dividend date on November 19, 2025 [3] - Mingtai Aluminum declared a cash dividend of RMB 0.10 per share (including tax), with the record date on November 18, 2025, and the ex-dividend date on November 19, 2025 [3]

（文章来源：证券日报） 证券日报网讯 11月10日晚间，圣诺生物发布公告称，2025年中期利润分配方案为每股现金红利0.03176 元（含税），股权登记日为2025年11月14日，除权（息）日为2025年11月17日。 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-032 成都圣诺生物科技股份有限公司 2025年中期权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次利润分配方案经公司2025 年 5 月 15 日的2024年年度股东大会授权董事会 在满足现金分红的条件下具体制定，并经 2025 年 10 月 27 日召开的第四届董事会 第二十七次会议审议通过。 二、 分配方案 重要内容提示： 1. 发放年度：2025年中期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/11/14 | 2025/11/17 | 2025/11/17 | 2. 分派对象： 一、 通过分配方案的股东会届次和日期 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 是否涉及差异化分红送转：否 每股分配比例 每股现金红利0.03176元 相关日期 3. 分配方案： 本次利润 ...

本次股权登记日：2025年11月14日；除权除息日为：2025年11月17日。 格隆汇11月10日丨圣诺生物(688117.SH)发布2025年半年度权益分派实施公告，分配方案的具体内容如 下：本次利润分配以方案实施前的公司总股本1.57亿股为基数，每股派发现金红利0.03176元（含税）， 共计派发现金红利499.86万元。 ...

Core Viewpoint - Shengnuo Bio (688117.SH) announced its profit distribution plan for the first half of 2025, detailing a cash dividend distribution to shareholders [1] Group 1: Dividend Distribution Details - The profit distribution is based on the company's total share capital of 157 million shares prior to the implementation of the plan [1] - A cash dividend of 0.03176 yuan per share (including tax) will be distributed, totaling 4.9986 million yuan [1] - The record date for the stock rights is set for November 14, 2025, and the ex-dividend date is November 17, 2025 [1]

Group 1 - The core advantage of generic drugs is the lower R&D investment required [1] - GLP-1 peptide drugs are well-known for their triple benefits: blood sugar reduction, weight loss, and cardiovascular protection, making them a highly competitive area in innovative pharmaceuticals [3] - Saintno Biological (688117.SH), a company listed on the Sci-Tech Innovation Board, focuses on providing CDMO services for innovative peptide drugs and developing raw materials and formulations for generic peptides [4][5] Group 2 - According to the third-quarter earnings forecast disclosed by Saintno Biological in mid-October, the expected net profit for the first three quarters is between 114 million to 140 million, representing a year-on-year growth of 100.53% to 145.10% [6] - The expected non-net profit for the same period is between 113 million to 138 million, with a year-on-year growth of 111.26% to 158.21% [6]